Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients

Journal of Chemotherapy

Volumn 24, Issue 2, 2012, Pages 107-112

  Petejova, Nadezda ^a   Zahalkova, Jana ^b,c   Duricova, Jana ^a   Kacirova, Ivana ^a   Brozmanova, Hana ^a   Urbanek, Karel ^d   Grundmann, Milan ^a   Martinek, Arnost ^a  

^a UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^b UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^c Hospital Sternberk   (Czech Republic)

^d PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Acute kidney injury; Continuous renal replacement therapy; Critically ill patients; Gentamicin dosing; Sepsis; Therapeutic drug monitoring

Indexed keywords

GENTAMICIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTINUOUS HEMOFILTRATION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DIURESIS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG MONITORING; FEMALE; HUMAN; KIDNEY FUNCTION; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; SEPSIS;

ACUTE KIDNEY INJURY; ADULT; AGED; ANTI-INFECTIVE AGENTS; CRITICAL ILLNESS; DRUG MONITORING; FEMALE; GENTAMICINS; HEMOFILTRATION; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; SEPSIS; TISSUE DISTRIBUTION;

EID: 84866243248     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/1120009X12Z.0000000006     Document Type: Article

References (22)

1. Ishikawa K, May CN, Gobe G, Langenberg C, Bellomo R. Pathophysiology of septic acute kidney injury: a different view of tubular injury. Contrib Nephrol. 2010;165:18-27.
2. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med. 2010;36(2):222-31.
3. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840-51.
4. Arzuaga A, Isla A, Gascón AR, Maynar J, Corral E, Pedraz JL. Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: evaluation of the sieving coefficient. Blood Purif. 2006;24(4):347-54.
5. Tetta C, Bellomo R, Kellum J, Ricci Z, Pohlmeiere R, Passlick-Deetjen J, et al. High volume hemofiltration in critically ill patients: why, when and how? Contrib Nephrol. 2004;144:362-75.
6. Ronco C, Tetta C, Mariano F, Wratten ML, Bonello M, Bordoni V, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs. 2003;27(9):792-801.
7. Choi G, Gomersall CD, Tian Q, Joynt GM, Li AM, Lipman J. Principles of antibacterial dosing in continuous renal replacement therapy. Blood Purif. 2010;30(3):195-212.
8. Dorman T, Swoboda S, Zarfeshenfard F, Trentler B, Lipsett PA. Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Crit Care Res Group Surg. 1998;124(1):73-8.
9. Myers DR, DeFehr J, Bennet WM, Porter GA, Olsen GD. Gentamicin binding to serum and plasma proteins. Clin Pharmacol Ther. 1978;23(3):356-60.
10. Kashuba AD, Nafziger AN, Drusano GL, Bertino JS, Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother. 1999;43(3):623-9.
11. Zarowitz BJ, Anandan JV, Dumler F, Jayashankar J, Levin N. Continuous arteriovenous hemofiltration of aminoglycoside antibiotics in critically ill patients. J Clin Pharmacol. 1986;26(8):686-9.
12. Ernest D, Cutler DJ. Gentamicin clearance during continuous arteriovenous hemodiafiltration. Crit Care Med. 1992;20(5):586-9.
13. Bohler J, Donauer J, Keller F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int Suppl. 1999;72:S24-8.
14. http://www.sukl.cz/download/spc/SPC92474.doc (gentamicin product information).
15. Tian Q, Gomersall CD, Ip M, Tan PE, Joynt GM, Choi GY. Adsorption of amikacin, a significant mechanism of elimination by hemofiltration. Antimicrob Agents Chemother. 2008;52(3):1009-13.
16. K N Lamp, Tian Q, Ip M, Gomersall CD. In vitroadsorption of gentamicin and netilmicin by polyacrylonitrile and polyamide hemofiltration filters. Antimicrob Agents Chemother. 2010;54(2):963-5.
17. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41(8):1159-66.
18. Dan M, Rossi S, Callegarin L, Ronco C. How to manage vasopressors in acute renal failure and septic shock. Contrib Nephrol. 2004;144:182-90.
19. Schentag JJ, Jusko WJ, Vance JW, Cumbo TJ, Abrutyn E, DeLattre M, et al. Gentamicin disposition and tissue accumulation on multiple dosing. J Pharmacokinet Biopharm. 1977;5(6):559-77.
20. Schentag JJ, Jusko WJ. Gentamicin persistence in the body. Lancet. 1977;1:486.
21. Bergeron MG, Trottier S. Influence of single or multiple doses of gentamicin and netilmicin on their cortical, medullary, and papillary distribution. Antimicrob Agents Chemother. 1979;15(5):635-41.
22. Roberts JA, Field J, Visser A, Whitbread R, Tallot M, Lipman J, et al. Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. Antimicrob Agents Chemother. 2010;54(9):3635-40.